Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01545518 · ClinicalTrials.gov registry record · Phase 2
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01545518 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 20 participants.
The verdict
NCT01545518, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients. This study consists of a single blood sample, which will be tested for possible immune abnormalities. If enough patients are found who show immune abnormalities, those patients who are still having uncontrolled seizures will be invited to participate in a study of immune treatment with a compound called intravenous immunoglobulin (IVIG). The study hypothesis is that a significant proportion of the young-onset, refractory, image-negative, partial-onset epilepsy population have an underlying autoimmune disorder, and many of these patients will respond to immune therapies, including IVIG. At present, the importance of immune abnormalities in causing epilepsy, and the proper treatment when they are found, are both poorly understood. The investigators hope that this study will help us understand the cause of some cases that are difficult to treat.
Interventions
- DRUG IVIG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01545518
The ClinicalTrials.gov registry entry for NCT01545518 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IVIG is the first listed.
NCT01545518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01545518 about?
NCT01545518 is a clinical study titled "IVIG Treatment for Refractory Immune-Related Adult Epilepsy". The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients. This study consists of a single blood sample, which will be tested for possible immune abnormalities. If enough patients are found who show immune abnormalities, those...
What is the current status of trial NCT01545518?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-11. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01545518?
The interventions under investigation include: IVIG (DRUG).
Who is sponsoring clinical trial NCT01545518?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.